Search

Your search keyword '"Crago, Aimee M."' showing total 311 results

Search Constraints

Start Over You searched for: Author "Crago, Aimee M." Remove constraint Author: "Crago, Aimee M."
311 results on '"Crago, Aimee M."'

Search Results

6. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

8. ASO Visual Abstract: Sentinel Lymph Node Biopsy for Extremity and Truncal Soft Tissue Sarcomas—A Systematic Review of the Literature

10. Current Management of Desmoid Tumors: A Review.

11. Supplementary Table S3 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

12. Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

13. Data from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

14. Supplementary Table S3 from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis

15. Data from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis

16. Supplementary Data 1 from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis

17. The association between tumor mutational burden and prognosis is dependent on treatment context

18. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

20. PDGFRβ signaling cooperates with β-catenin to modulate c-Abl and biologic behavior of desmoid-type fibromatosis

21. Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

24. Supplementary Data 2 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

25. Supplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

26. Supplementary Data 3 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

28. Data from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

29. Supplementary Tables S1 - S7 from Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma

30. Data from Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma

31. Supplementary Figures S1 - S8 from Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma

32. Supplementary Figure Legends from Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma

34. Data from Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors

35. Supplementary Data from A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

37. Data from A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

41. Supplementary Figure from Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors

50. Supplementary Data from Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors

Catalog

Books, media, physical & digital resources